Dr. Younes Agoumi, MD FRCSC
Claim this profileCentre Hospitalier de l'Université de Montréal (CHUM)
Studies Glaucoma
Studies Open-Angle Glaucoma
5 reported clinical trials
9 drugs studied
Affiliated Hospitals
Clinical Trials Younes Agoumi, MD FRCSC is currently running
Laser Treatment
for Glaucoma Prevention in Corneal Disease
The Boston keratoprosthesis (KPro) is a special plastic device that is used to replace a sick cornea (transparent part of the eye, in front of the iris) in order to restore vision in patients who have failed traditional corneal transplants or have a very poor prognosis of success. Glaucoma is a chronic disease which causes optic nerve damage secondary to high pressure inside the eye and could lead to vision loss in the long term. Glaucoma is highly prevalent in patients who require a KPro and even more after their procedure. In order to decrease the intra-ocular pressure, surgeons can use multiple eyedrops. Unfortunately, following the KPro surgery, eyedrops lose their efficiency because they are less absorbed by the eye. The transscleral cyclophotocoagulation (TS-CPC) is a laser treatment used in advanced refractory glaucoma. This laser helps decrease the intra-ocular pressure and have a better control of the disease. There are different methods of laser transmission, including the continuous transmission (G-Probe) and the micro-pulsation method (Micopulse). Given the high prevalence of glaucoma in patients receiving a KPro, the investigators are studying the effect of giving the TS-CPC treatment prophylactically to patients before their Boston keratoprosthesis. Our hypothesis is that prophylactic TS-CPC will decrease glaucoma progression as well as the risks of developing glaucoma following the Boston keratoprosthesis . METHOD The investigators aim to recruit twenty (20) patients who are scheduled to receive Boston KPro. Participants will be randomized into two groups: 1) Groupe 1 will receive a prophylactic treatment of transscleral cyclophotocoagulation a G-Probe. 2) Groupe 2 will receive a prophylactic treatment of transscleral cyclophotocoagulation with a micropulse transmission (MicroPulse). The patients will receive their laser treatment by a glaucoma specialist 4 to 8 weeks before their KPro surgery. One week following their laser treatment, the participants will be examined by their glaucoma specialist. Following their KPro surgery, patients will have a follow-up at day-1, weeks 1 and 2, months 1 and 3, then every 4 to 6 months for 5 years. Additional non-invasive glaucoma tests will be performed twice during the first 3 months following the surgery and will be repeated every 4-6 months. Visual acuity results, the visual field tests and rates of post-operative complications will be compared between the different groups.
Recruiting1 award N/A
GDD Timing with Boston KPro
for Glaucoma
Boston keratoprosthesis (KPro) is a piece of specialized plastic that replace sick cornea (transparent structure at the front of the eye) in patients who have failed or those who are expected to have poor results with traditional corneal transplantation. While the Kpro can offer dramatic improvement in vision, it is also associated with several complications. Glaucoma (optic nerve damage due to high pressure inside the eye) is one of the most common complications after KPro surgery and can potentially cause irreversible vision loss. The implantation of a glaucoma drainage device (GDD), a tiny tube that drains the liquid inside the eye by bypassing the natural drainage system, is an effective option to lower the eye pressure in patients with KPro. Given the frequency and potentially devastating effects of glaucoma among KPro patients, some surgeons recommend to put in a GDD as a preventative measure. However, there is no consensus on when is the best timing to perform such surgery in relation to the Boston Kpro surgery. Hypothesis: For patients undergoing the Boston KPro surgery, implanting a GDD simultaneously, at the time of surgery, is more efficacious than at 6 months later, in the prevention of the progression of glaucoma and in maintaining better visual functions. Methods: The investigators aim to recruit 40 patients over 4 years. Recruited patients will be randomly assigned to 2 groups: 1) simultaneous GDD implantation at the Boston KPro surgery, and 2) GDD implantation 6 months after the Boston KPro surgery. Once recruited, patients will be followed before the KPro surgery, postoperative day 1, week 1, month 1, 3, 6 and 12. Standard ophthalmological exam will be performed at each visit. Additional non-invasive glaucoma tests and evaluation (visual fields and optic nerve photo) will be performed on day 1, month 1, 3, 6 and 12. For patients assigned to group 2, a GDD will be implanted 6 months after the KPro surgery. They will have additional follow-ups on post-GDD surgery day 1, week 1 and month 1. Results of visual acuity, visual fields, optic nerve evaluation and complications will be compared between the two groups to determine the better timing of GDD implantation.
Recruiting1 award N/A5 criteria
More about Younes Agoumi, MD FRCSC
Clinical Trial Related4 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Younes Agoumi, MD FRCSC has experience with
- Topical Insulin Drops
- Transscleral Cyclphophotocoagulation Using The Micropulse System
- G-Probe Transscleral Cyclphophotocoagulation
- Boston Keratoprosthesis Type 1
- Glaucoma Drainage Device
- Corneal Topography: Pentacam
Breakdown of trials Younes Agoumi, MD FRCSC has run
Glaucoma
Open-Angle Glaucoma
Corneal Disease
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Younes Agoumi, MD FRCSC specialize in?
Younes Agoumi, MD FRCSC focuses on Glaucoma and Open-Angle Glaucoma. In particular, much of their work with Glaucoma has involved treating patients, or patients who are undergoing treatment.
Is Younes Agoumi, MD FRCSC currently recruiting for clinical trials?
Yes, Younes Agoumi, MD FRCSC is currently recruiting for 3 clinical trials in Montreal Quebec. If you're interested in participating, you should apply.
Are there any treatments that Younes Agoumi, MD FRCSC has studied deeply?
Yes, Younes Agoumi, MD FRCSC has studied treatments such as Topical Insulin Drops, Transscleral cyclphophotocoagulation using the Micropulse system, G-Probe transscleral cyclphophotocoagulation.
What is the best way to schedule an appointment with Younes Agoumi, MD FRCSC?
Apply for one of the trials that Younes Agoumi, MD FRCSC is conducting.
What is the office address of Younes Agoumi, MD FRCSC?
The office of Younes Agoumi, MD FRCSC is located at: Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec H2X 3E4 Canada. This is the address for their practice at the Centre Hospitalier de l'Université de Montréal (CHUM).
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.